Akorn (AKRX) Rating Reiterated by Deutsche Bank

Deutsche Bank reissued their hold rating on shares of Akorn (NASDAQ:AKRX) in a research note published on Thursday morning.

AKRX has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Akorn from a hold rating to a sell rating in a report on Wednesday, January 24th. Piper Jaffray set a $34.00 price objective on shares of Akorn and gave the company a hold rating in a report on Wednesday, March 7th. William Blair reissued a hold rating on shares of Akorn in a report on Thursday, March 1st. BidaskClub downgraded shares of Akorn from a sell rating to a strong sell rating in a report on Saturday, January 20th. Finally, Royal Bank of Canada set a $25.00 target price on shares of Akorn and gave the company a hold rating in a research report on Thursday, March 29th. Two analysts have rated the stock with a sell rating and seven have issued a hold rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $31.75.

NASDAQ AKRX traded down $0.04 during trading on Thursday, reaching $18.18. The company’s stock had a trading volume of 225,478 shares, compared to its average volume of 2,031,824. The company has a quick ratio of 3.19, a current ratio of 4.27 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $2,284.71, a P/E ratio of 8.40, a P/E/G ratio of 0.84 and a beta of 1.69. Akorn has a 12 month low of $16.79 and a 12 month high of $34.00.



In other news, major shareholder John N. Kapoor sold 13,629 shares of the business’s stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $32.67, for a total value of $445,259.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.20% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of the company. BlackRock Inc. raised its position in shares of Akorn by 2.8% in the 4th quarter. BlackRock Inc. now owns 7,958,348 shares of the company’s stock valued at $256,496,000 after buying an additional 215,686 shares in the last quarter. Twin Securities Inc. increased its position in Akorn by 190.8% during the 4th quarter. Twin Securities Inc. now owns 3,767,422 shares of the company’s stock worth $121,424,000 after purchasing an additional 2,471,711 shares in the last quarter. Gardner Lewis Asset Management L P increased its position in Akorn by 65.0% during the 4th quarter. Gardner Lewis Asset Management L P now owns 3,670,371 shares of the company’s stock worth $118,296,000 after purchasing an additional 1,445,923 shares in the last quarter. Renaissance Technologies LLC increased its position in Akorn by 5.2% in the 4th quarter. Renaissance Technologies LLC now owns 2,832,600 shares of the company’s stock valued at $91,295,000 after acquiring an additional 139,100 shares during the period. Finally, Deutsche Bank AG increased its position in Akorn by 8.7% in the 4th quarter. Deutsche Bank AG now owns 2,037,471 shares of the company’s stock valued at $65,666,000 after acquiring an additional 163,367 shares during the period. Institutional investors own 78.24% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Akorn (AKRX) Rating Reiterated by Deutsche Bank” was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://dakotafinancialnews.com/2018/04/13/akorn-akrx-rating-reiterated-by-deutsche-bank.html.

Akorn Company Profile

Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.

Analyst Recommendations for Akorn (NASDAQ:AKRX)

Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply